Apotex has received the U.S. FDA’s first Tentative Approval for its Abbreviated New Drug Application for semaglutide injection. In short, Apotex says, it is a “significant milestone” opening a pathway to a generic version of Novo Nordisk’s Ozempic. Apotex Partners With Orbicular The treatment was developed through a strategic partnership with Orbicular Pharmaceutical Technologies, said Apotex Chief Corporate Development Officer Barry Fishman. This collaboration brought together sophisticat...